Bulletin from the annual general meeting in Cyxone AB on 16 May 2022

Today, on 16 May 2022, the annual general meeting was held in Cyxone AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the proposal from the board of directors to allocate the company's result, meaning that no dividends are paid and that available funds are carried forward.

The annual general meeting resolved to discharge the members of the board of directors and the CEO from liability for the financial year 2021.

The annual general meeting resolved to re-elect Bert Junno, Theresa Comiskey Olsen, Saad Gilani and Mikael Lindstam as board members. Bert Junno was re-elected as Chairman of the board of directors.

Furthermore, the annual general meeting resolved that board remuneration shall be paid with SEK 400,000 to the Chairman of the board of directors, and with SEK 200,000 to each of the other board members.

Finally, the annual general meeting resolved to re-elect the accounting firm KPMG AB as auditor, and that remuneration for the auditor shall be paid in accordance with approved invoice. KPMG AB has informed that the authorized public accountant Camilla Alm Andersson will continue to be the auditor in charge.

The annual general meeting resolved, in accordance with the proposal from the board of directors, that an instruction and charter for the Nomination Committee shall be adopted. The Nomination Committee shall be comprised of four members, representing the three largest shareholders as per the end of September, together with the Chairman of the board of directors. No fees shall be paid to the members of the Nomination Committee.

The annual general meeting resolved, in accordance with the proposal from the board of directors, on guidelines for remuneration to senior executives.

The annual general meeting resolved, in accordance with the proposal from the board of directors, to amend 1 § regarding an editorial change of “company name” (Sw. företagsnamn), to amend 4-5 §§ so that the limits for the share capital and number of shares in the company are amended and to amend 9 § so that the day for registration in the share ledger is not expressed as it is derived from the Swedish Companies Act.

The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors to resolve, on one or several occasions before the next annual general meeting, to issue new shares, warrants or convertibles with preferential rights for the share-holders or conditional upon payment in-kind. As regards to the preferential issue, the payment may be in cash or through set-off. The total number of shares that may be issued, or, as regards issue of convertibles or warrants, issued by conversion or exercise, under the authorization shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered articles of association.

The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors to resolve, on one or several occasions before the next annual general meeting, to issue new shares, warrants or convertibles with deviation from the shareholders’ preferential rights. Shares, warrants or convertibles may be issued for cash payment or payment through set-off. The total number of shares that may be issued, or, as regards issue of convertibles or warrants, issued by conversion or exercise, under the authorization shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered articles of association. An issue adopted on the basis of the authorization, shall be made on market terms (meaning that an issue discount in line with prevailing market conditions may be granted).

Malmö on 16 May 2022
Cyxone AB (publ)

Contact

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

The information was submitted for publication, through the agency of the contact person set out above, at 11.00 a.m. CEST on 16th of May 2022.

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. For more information, please visit www.cyxone.com